Brief Summary
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advancedat a late stage, far along solid tumor malignancies and clear cell renal cell carcinomacancer arising from tissues that line organs (ccRCC) during the dosethe amount of medication taken escalation stage; and
- casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage.
Intervention / Treatment
- Drug: Casdatifan
- Drug: Zimberelimab
Inclusion Criteria:
- Must have at least one measurable lesion per RECIST guidance
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status score of ≤ 1
- Disease-specific criteria for dose escalation:
- Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
- Creatinine clearance ≥ 40 mL/min
Disease-specific criteria for dose-expansion:
- Histologically confirmed ccRCC
- Creatinine clearance ≥ 40 mL/min